TrontinemabA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Sponsor:

Hoffmann-La Roche

Code:

NCT07169578

Conditions

Alzheimers Disease

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Interventions

Trontinemab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-20. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-06.